Seegene Inc
KOSDAQ:096530
Seegene Inc
Cash & Cash Equivalents
Seegene Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
Seegene Inc
KOSDAQ:096530
|
Cash & Cash Equivalents
â‚©214.9B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
37%
|
CAGR 10-Years
29%
|
|
Celltrion Inc
KRX:068270
|
Cash & Cash Equivalents
â‚©564.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
1%
|
CAGR 10-Years
15%
|
||
SK Bioscience Co Ltd
KRX:302440
|
Cash & Cash Equivalents
â‚©127B
|
CAGR 3-Years
72%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
||
H
|
Hugel Inc
KOSDAQ:145020
|
Cash & Cash Equivalents
â‚©182.9B
|
CAGR 3-Years
61%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash & Cash Equivalents
â‚©114.6B
|
CAGR 3-Years
53%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash & Cash Equivalents
â‚©27B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
Seegene Inc
Glance View
Seegene, Inc. engages in the manufacturing and distributing of molecular diagnostics and reagents. The company is headquartered in Seoul, Seoul. The company went IPO on 2010-09-10. The firm mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The firm provides its products under the brand names of Seeplex, Anyplex and Magicplex. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Seegene Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
214.9B
KRW
Based on the financial report for Sep 30, 2024, Seegene Inc's Cash & Cash Equivalents amounts to 214.9B KRW.
What is Seegene Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
29%
Over the last year, the Cash & Cash Equivalents growth was 20%. The average annual Cash & Cash Equivalents growth rates for Seegene Inc have been -18% over the past three years , 37% over the past five years , and 29% over the past ten years .